CD8A and neoplasm: Trials in both the neoadjuvant and adjuvant setting should be conducted due to recent publications showing the Adora2 receptors can promote tumor growth, metastasis and reduce CD8+ T cell anti-tumor immunity predominantly in preclinical models (3, 4, 11, 120, 123–126, 137–144).